Tipsheet
What matters at India’s listed companies
Earnings · Healthcare · Micro cap

Kerala Ayurveda reports revenue growth but losses widen for FY26

Standalone revenue climbed 17.6% to ₹85.48 crore, yet net losses deepened to ₹14.74 crore as the company struggles to turn a profit.

2 earlier stories on Kerala Ayurveda Ltd.
Mkt cap₹274 cr
ROE0.00%
Debt / eq.6.95
₹20.65 cr Consolidated net loss for the full year ended March 31, 2026.

What's new

  • Standalone revenue rose 17.6% to ₹85.48 crore; consolidated revenue grew 9% to ₹131.15 crore.
  • Net losses widened to ₹14.74 crore (standalone) and ₹20.65 crore (consolidated).
  • Auditors flagged significant outstanding trade receivables from subsidiaries without provisions.

Why this matters

Revenue growth is failing to translate into profitability, with losses expanding on both a standalone and consolidated basis. The auditor's note on unprovided receivables from subsidiaries raises questions about the quality of the company's balance sheet.

What we're watching

  • Management's plan to address the widening net losses.
  • Any movement on the outstanding receivables from subsidiaries.
  • Whether the company can achieve operational break-even in FY27.

The full read

Kerala Ayurveda posted revenue growth for the year ended March 31, 2026, but the company's financial health remains strained. Standalone revenue grew 17.6% to ₹85.48 crore, while consolidated revenue rose 9% to ₹131.15 crore. Despite these gains, net losses deepened. The standalone net loss widened to ₹14.74 crore from ₹13.78 crore in the prior year, and the consolidated net loss reached ₹20.65 crore. The audit report contains an emphasis of matter regarding significant trade receivables from subsidiaries that lack provisions. This points to a persistent struggle to convert revenue into profit while managing inter-company balances. These results are a routine annual disclosure. The combination of widening losses and unprovided subsidiary receivables leaves little room for optimism.

Questions answered

How did Kerala Ayurveda perform in FY26?
The company saw top-line growth, with standalone revenue rising 17.6% to ₹85.48 crore and consolidated revenue increasing 9% to ₹131.15 crore. Bottom-line performance deteriorated, with standalone losses widening to ₹14.74 crore and consolidated losses reaching ₹20.65 crore.
What concern did the auditors raise?
The audit report includes an emphasis of matter regarding significant trade receivables owed by subsidiaries. These amounts remain outstanding without any provisions made against them.
Is this a new development for the company?
No. The results continue a trend of operating losses, and the filing represents a routine annual financial disclosure.
Mentioned: Kerala Ayurveda Ltd
Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.

  1. 25 May 2026 · 7:46 PM IST Kerala Ayurveda reports revenue growth but losses widen for FY26
  2. today Kerala Ayurveda reports wider losses despite double-digit revenue growth
  3. today Kerala Ayurveda reports revenue growth alongside widening annual losses